title: Drugs of last resort? The use of polymyxins and tigecycline at US Veterans Affairs medical centers, 2005-2010.
abstract: Multidrug-resistant (MDR) and carbapenem-resistant (CR) Gram-negative pathogens are becoming increasingly prevalent around the globe. Polymyxins and tigecycline are among the few antibiotics available to treat infections with these bacteria but little is known about the frequency of their use. We therefore aimed to estimate the parenteral use of these two drugs in Veterans Affairs medical centers (VAMCs) and to describe the pathogens associated with their administration. For this purpose we retrospectively analyzed barcode medication administration data of parenteral administrations of polymyxins and tigecycline in 127 acute-care VAMCs between October 2005 and September 2010. Overall, polymyxin and tigecycline use were relatively low at 0.8 days of therapy (DOT)/1000 patient days (PD) and 1.6 DOT/1000PD, respectively. Use varied widely across facilities, but increased overall during the study period. Eight facilities accounted for three-quarters of all polymyxin use. The same statistic for tigecycline use was twenty-six VAMCs. There were 1,081 MDR or CR isolates during 747 hospitalizations associated with polymyxin use (1.4/hospitalization). For tigecycline these number were slightly lower: 671 MDR or CR isolates during 500 hospitalizations (1.3/hospitalization) (p = 0.06). An ecological correlation between the two antibiotics and combined CR and MDR Gram-negative isolates per 1000PD during the study period was also observed (Pearson's correlation coefficient r = 0.55 polymyxin, r = 0.19 tigecycline). In summary, while polymyxin and tigecycline use is low in most VAMCs, there has been an increase over the study period. Polymyxin use in particular is associated with the presence of MDR Gram-negative pathogens and may be useful as a surveillance measure in the future.
authors.affiliation: VA Salt Lake City Health Care System and University of Utah, Salt Lake City, Utah, United States of America.
authors.forename: Benedikt
authors.initials: B
authors.lastname: Huttner
authors.forename: Makoto
authors.initials: M
authors.lastname: Jones
authors.forename: Michael A
authors.initials: MA
authors.lastname: Rubin
authors.forename: Melinda M
authors.initials: MM
authors.lastname: Neuhauser
authors.forename: Adi
authors.initials: A
authors.lastname: Gundlapalli
authors.forename: Matthew
authors.initials: M
authors.lastname: Samore
mesh_terms: D017723:Drug Utilization Review; D006787:Hospitals, Veterans / Q000458:organization & administration*; D008911:Minocycline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011113:Polymyxins / Q000627:therapeutic use*; D000078304:Tigecycline; D014481:United States
chemical_list: D011113:Polymyxins; D000078304:Tigecycline; D008911:Minocycline